ReviewMicrobiological reviews1995
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.
Review in Microbiological reviews, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Estimating the impact of pneumococcal conjugate vaccines on childhood pneumonia in sub-Saharan Africa: A systematic review.F1000Research · 2020Pooled it
- Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.Infection and immunity · 1997Trial
- Routine immunization againstThe Lancet regional health. Southeast Asia · 2024Article
- Article
- Emerging vaccine strategies against the incessant pneumococcal disease.NPJ vaccines · 2023Review
- Comparative genomic analysis of two ST320 Streptococcus pneumoniae isolates, representing serotypes 19A and 19F.BMC genomic data · 2023Article
- Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods.Bioengineering (Basel, Switzerland) · 2022Review
- Pneumococcal carriage in unvaccinated children at the time of vaccine implementation into the national immunization program in Poland.Scientific reports · 2022Article
- Article
- Biochemical Characterization and Synthetic Application of WciN and Its Mutants FromFrontiers in chemistry · 2022Article
- Pneumococcal Serotype Identification by Capsular Sequence Typing (CST): A Modified Novel Approach for Serotyping Directly in Clinical Samples.Diagnostics (Basel, Switzerland) · 2021Article
- Contribution of NmSystems · 2021Article
- Synthetic Analogs ofRussian journal of bioorganic chemistry · 2021Article
- Sequential Linkage of Carbohydrate Antigens to Mimic Capsular Polysaccharides: Toward Semisynthetic Glycoconjugate Vaccine Candidates againstACS chemical biology · 2020Article
- Synthesis ofBeilstein journal of organic chemistry · 2020Article
- Next-Generation Whole-Cell Pneumococcal Vaccine.Vaccines · 2019Review
- Asymptomatic carriage of Streptococcus pneumoniae detected by qPCR on the palm of hands of populations in rural Senegal.PLoS neglected tropical diseases · 2018Article
- Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid.mAbs · 2018Article
- Article
- Serotypes & penicillin susceptibility ofThe Indian journal of medical research · 2018Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although pneumococcal conjugate vaccines are close to being licensed, a more profound knowledge of the virulence factors responsible for the morbidity and mortality caused by Streptococcus pneumoniae is necessary. This review deals with the major structures of pneumococci involved in the pathogenesis of pneumococcal disease and their interference with the defense mechanisms of the host. It is well known that protection against S. pneumoniae is the result of phagocytosis of invading pathogens. For this process, complement and anticapsular polysaccharide antibodies are required. Besides, relatively recent experimental data suggest that protection is also mediated by the removal of disintegrating pneumococci and their degradation products (cell wall, pneumolysin). These structures seem to be major contributors to illness and death caused by pneumococci. An effective conjugate vaccine should therefore preferably include the capsular polysaccharide and at least one of these inflammatory factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.